(Q53222425)

English

Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis.

scientific article published on 31 August 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

author name string

Peter Stärkel

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Nicolas Charette

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Ivan Borbath

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Tanja Schneider-Merck

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Christine De Saeger

5

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Jorge Abarca

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Isabelle Leclercq

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Yves Horsmans

8

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

publication date

31 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Molecular Carcinogenesis

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

51

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

10

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

816-825

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Novel advancements in the management of hepatocellular carcinoma in 2008.

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Blocking oncogenic Ras signaling for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Dislodgment and accelerated degradation of Ras.

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid).

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Selective Inhibition of Ras-dependent Cell Growth by Farnesylthiosalisylic Acid

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats.

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Molecular prognostication of liver cancer: end of the beginning

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Experimental models of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Application of comparative functional genomics to identify best-fit mouse models to study human cancer

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver.

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

NF-κB and STAT3 - key players in liver inflammation and cancer

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Oncogenic activation of NF-kappaB.

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

STAT3 as a central mediator of neoplastic cellular transformation

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

G protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Ha-ras oncogene-induced Stat3 phosphorylation enhances oncogenicity of the cell

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation.

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

MSK activation and physiological roles

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

The mTOR pathway: a new target in cancer therapy.

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease

1 reference

https://api.crossref.org/works/10.1002%2FMC.20849

21 January 2018

Identifiers

10.1002/MC.20849

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21882255

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53222425&oldid=825188474"